Title(s):
Professor of Urology
Professor of Oncology
Professor of Oncology
Urology
Professor
Director of Adult Urology
Professor
Director of Adult Urology
Appointment Phone:
410-955-6100
Primary Location:
Johns Hopkins Outpatient Center
Expertise:
Active Surveillance of Prostate Cancer, Benign Prostatic Hyperplasia, Prostate Cancer, Urologic Oncology - Carcinoma of the Prostate, Urology, Urology / Urologic Surgery, Urology, Adult
Education and Experience
Training
- Medical University of South Carolina College of Medicine (Charleston SC)/ (1981)
Residencies
- The New York Hospital/Cornell Medical Center (New York NY)/ Urology (1987)
- The New York Hospital/Cornell Medical Center (New York NY)/ Surgery (1983)
Fellowships
- Johns Hopkins University School of Medicine (Baltimore MD)/ Urology (1989)
Certifications
- Urology, American Board of Urology (2010)
Locations
Johns Hopkins Outpatient Center
601 N. Caroline Street
Baltimore, MD 21287
Phone: 410-955-0351
Appointment Phone: 410-955-6100
Fax: 410-955-0833
Location Map
The Johns Hopkins Hospital
600 N. Wolfe Street
Hospital Main Entrance - Sheikh Zayed Tower
Baltimore, MD 21287
Phone: 410-955-0351
Appointment Phone: 410-955-6100
Fax: 410-955-0833
Location Map
Department / Division
- Urology
Centers/Institutes
Centers / Institutes
- Brady Urological Institute
- Sidney Kimmel Comprehensive Cancer Center
Bio
Physician Title
Urology
Professor
Director of Adult Urology
Professor
Director of Adult Urology
Expertise
- Active Surveillance of Prostate Cancer
- Benign Prostatic Hyperplasia
- Prostate Cancer
- Urologic Oncology - Carcinoma of the Prostate
- Urology
- Urology / Urologic Surgery
- Urology, Adult
Research
Research and Publications
Research Summary
Dr. Carter pioneered the concept of PSA rate of change (PSA velocity) as a marker of prostate cancer presence and the use of free PSA to predict the behavior of prostate cancer. He was the first to publish data demonstrating that an individuals personal prostate cancer screening program should be tailored to baseline PSA levels performed at an early age instead of using a one size fits all approach. Together with investigators at the Baltimore Longitudinal Study of Aging, Dr. Carter has investigated risk factors for development of prostate cancer and prostate enlargement including diet and life style.
Dr. Carter runs the Expectant Management Program for prostate cancer at Johns Hopkins. This program is designed to select men who are thought to have small volume cancers for whom no immediate treatment is a rational management option. In this program, Dr. Carter together with colleagues at the Brady Urological Institute, are seeking to define the biomarker changes, nuclear structural parameters, genetic profile, and diet/lifestyle factors that may help identify which men with prostate caner can safely forgo treatment for prostate cancer
Journal Citations
Carter, H.B.; Ferrucci, L.; Kettermann, A.; Landis, P.; Wright, E.J.; Epstein, J.I.; Trock, B.J.; Metter, E.J. Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst. 2006 Nov 1;98(21):1521-1527.
Makarov, D.V.; Carter, H.B. The discovery of prostate specific antigen as a biomarker for the early detection of adenocarcinoma of the prostate. J Urol. 2006 Dec;176(6 Pt 1):2383-2385.
Martin, P.J.; Weisdorf, D.; Przepiorka, D.; Hirschfeld, S.; Farrell, A.; Rizzo, J.D.; Foley, R.; Socie, G.; Carter, S.; Couriel, D.; Schultz, K.R.; Flowers, M.E.; Filipovich, A.H.; Saliba, R.; Vogelsang, G.B.; Pavletic, S.Z.; Lee, S.J. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. Design of Clinical Trials Working Group report. Biol Blood Marrow Transplant. 2006 May;12(5):491-505.
Parsons, J.K.; Carter, H.B.; Partin, A.W.; Windham, B.G.; Metter, E.J.; Ferrucci, L.; Landis, P.; Platz, E.A. Metabolic factors associated with benign prostatic hyperplasia. J Clin Endocrinol Metab. 2006 Jul;91(7):2562-2568.
Richman, J.M.; Carter, H.B.; Hanna, M.N.; Murphy, J.D.; Rowlingson, A.J.; Andrews, R.A.; Wu, C.L. Efficacy of periprostatic local anesthetic for prostate biopsy analgesia: a meta-analysis. Urology. 2006 Jun;67(6):1224-1228.
Warlick, C.; Trock, B.J.; Landis, P.; Epstein, J.I.; Carter, H.B. Delayed versus immediate surgical intervention and prostate cancer outcome. J Natl Cancer Inst. 2006 Mar 1;98(5):355-357.
Warlick, C.A.; Allaf, M.E.; Carter, H.B. Expectant treatment with curative intent in the prostate-specific antigen era: triggers for definitive therapy. Urol Oncol. 2006 Jan-Feb;24(1):51-57.
Berdeja, J.G.; Hess, A.; Lucas, D.M.; O'Donnell, P.; Ambinder, R.F.; Diehl, L.F.; Carter-Brookins, D.; Newton, S.; Flinn, I.W. Systemic interleukin-2 and adoptive transfer of lymphokine-activated killer cells improves antibody-dependent cellular cytotoxicity in patients with relapsed B-cell lymphoma treated with rituximab. Clin Cancer Res. 2007 Apr 15;13(8):2392-2399.
Carlson, R.W.; Anderson, B.O.; Burstein, H.J.; Carter, W.B.; Edge, S.B.; Farrar, W.B.; Goldstein, L.J.; Gradishar, W.J.; Hayes, D.F.; Hudis, C.A.; Jahanzeb, M.; Ljung, B.M.; Kiel, K.; Marks, L.B.; McCormick, B.; Nabell, L.M.; Pierce, L.J.; Reed, E.C.; Silver, S.M.; Smith, M.L.; Somlo, G.; Theriault, R.L.; Ward, J.H.; Winer, E.P.; Wolff, A.C. Invasive breast cancer. J Natl Compr Canc Netw. 2007 Mar;5(3):246-312.
Carter, H.B.; Kettermann, A.; Ferrucci, L.; Landis, P.; Metter, E.J. Prostate-specific antigen velocity risk count assessment: a new concept for detection of life-threatening prostate cancer during window of curability. Urology. 2007 Oct;70(4):685-690.
Carter, H.B.; Kettermann, A.; Warlick, C.; Metter, E.J.; Landis, P.; Walsh, P.C.; Epstein, J.I. Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience. J Urol. 2007 Dec;178(6):2359-2364; discussion 2364-2355.
Gonzalgo, M.L.; Carter, H.B. Update on PSA testing. J Natl Compr Canc Netw. 2007 Aug;5(7):737-742.
Kawachi, M.H.; Bahnson, R.R.; Barry, M.; Carroll, P.R.; Carter, H.B.; Catalona, W.J.; Epstein, J.I.; Etzioni, R.B.; Hemstreet, G.P., 3rd; Howe, R.J.; Kopin, J.D.; Lange, P.H.; Lilja, H.; Mohler, J.; Moul, J.; Nadler, R.B.; Patterson, S.; Pollack, A.; Presti, J.C.; Stroup, A.M.; Urban, D.A.; Wake, R.; Wei, J.T. Prostate cancer early detection. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2007 Aug;5(7):714-736.
Keller, E.T.; Rowley, D.R.; Tomlins, S.A.; Drake, C.G.; Kantoff, P.W.; Pienta, K.J.; Montie, J.E.; Carter, H.B.; Hruszkewicz, A.M.; Gomez, J.; Mohla, S.; Getzenberg, R.H. Eleventh Prouts Neck Meeting on Prostate Cancer: emerging strategies in prostate cancer therapy. Cancer Res. 2007 Oct 15;67(20):9613-9615.
Magheli, A.; Rais-Bahrami, S.; Carter, H.B.; Peck, H.J.; Epstein, J.I.; Gonzalgo, M.L. Subclassification of clinical stage T1 prostate cancer: impact on biochemical recurrence following radical prostatectomy. J Urol. 2007 Oct;178(4 Pt 1):1277-1280; discussion 1280-1271.
Berkowitz, J.; Carter, H.B.; Gearhart, J.P. Prostate cancer in patients with the bladder exstrophy-epispadias complex: insights and outcomes. Urology. 2008 Jun;71(6):1064-1066.
Jones, S.; Zhang, X.; Parsons, D.W.; Lin, J.C.; Leary, R.J.; Angenendt, P.; Mankoo, P.; Carter, H.; Kamiyama, H.; Jimeno, A.; Hong, S.M.; Fu, B.; Lin, M.T.; Calhoun, E.S.; Kamiyama, M.; Walter, K.; Nikolskaya, T.; Nikolsky, Y.; Hartigan, J.; Smith, D.R.; Hidalgo, M.; Leach, S.D.; Klein, A.P.; Jaffee, E.M.; Goggins, M.; Maitra, A.; Iacobuzio-Donahue, C.; Eshleman, J.R.; Kern, S.E.; Hruban, R.H.; Karchin, R.; Papadopoulos, N.; Parmigiani, G.; Vogelstein, B.; Velculescu, V.E.; Kinzler, K.W. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008 Sep 26;321(5897):1801-1806.
Loeb, S.; Kettermann, A.; Carter, H.B.; Ferrucci, L.; Metter, E.J.; Walsh, P.C. Does prostate growth confound prostate specific antigen velocity? Data from the Baltimore longitudinal study of aging. J Urol. 2008 Oct;180(4):1314-1317; discussion 1317.
Loeb, S.; Kettermann, A.; Ferrucci, L.; Landis, P.; Metter, E.J.; Carter, H.B. PSA doubling time versus PSA velocity to predict high-risk prostate cancer: data from the Baltimore Longitudinal Study of Aging. Eur Urol. 2008 Nov;54(5):1073-1080.
Makarov, D.V.; Marlow, C.; Epstein, J.I.; Miller, M.C.; Landis, P.; Partin, A.W.; Carter, H.B.; Veltri, R.W. Using nuclear morphometry to predict the need for treatment among men with low grade, low stage prostate cancer enrolled in a program of expectant management with curative intent. Prostate. 2008 Feb 1;68(2):183-189.
Osunkoya, A.O.; Carter, H.B.; Epstein, J.I. A clinicopathologic study of preoperative and postoperative findings with minute Gleason 3+3=6 cancer at radical prostatectomy. Urology. 2008 Sep;72(3):638-640.
Parsons, D.W.; Jones, S.; Zhang, X.; Lin, J.C.; Leary, R.J.; Angenendt, P.; Mankoo, P.; Carter, H.; Siu, I.M.; Gallia, G.L.; Olivi, A.; McLendon, R.; Rasheed, B.A.; Keir, S.; Nikolskaya, T.; Nikolsky, Y.; Busam, D.A.; Tekleab, H.; Diaz, L.A., Jr.; Hartigan, J.; Smith, D.R.; Strausberg, R.L.; Marie, S.K.; Shinjo, S.M.; Yan, H.; Riggins, G.J.; Bigner, D.D.; Karchin, R.; Papadopoulos, N.; Parmigiani, G.; Vogelstein, B.; Velculescu, V.E.; Kinzler, K.W. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008 Sep 26;321(5897):1807-1812.
Roddam, A.W.; Allen, N.E.; Appleby, P.; Key, T.J.; Ferrucci, L.; Carter, H.B.; Metter, E.J.; Chen, C.; Weiss, N.S.; Fitzpatrick, A.; Hsing, A.W.; Lacey, J.V., Jr.; Helzlsouer, K.; Rinaldi, S.; Riboli, E.; Kaaks, R.; Janssen, J.A.; Wildhagen, M.F.; Schroder, F.H.; Platz, E.A.; Pollak, M.; Giovannucci, E.; Schaefer, C.; Quesenberry, C.P., Jr.; Vogelman, J.H.; Severi, G.; English, D.R.; Giles, G.G.; Stattin, P.; Hallmans, G.; Johansson, M.; Chan, J.M.; Gann, P.; Oliver, S.E.; Holly, J.M.; Donovan, J.; Meyer, F.; Bairati, I.; Galan, P. Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies. Ann Intern Med. 2008 Oct 7;149(7):461-471, W483-468.
Schroder, F.H.; Carter, H.B.; Wolters, T.; van den Bergh, R.C.; Gosselaar, C.; Bangma, C.H.; Roobol, M.J. Early detection of prostate cancer in 2007. Part 1: PSA and PSA kinetics. Eur Urol. 2008 Mar;53(3):468-477.
Sheridan, T.B.; Carter, H.B.; Wang, W.; Landis, P.B.; Epstein, J.I. Change in prostate cancer grade over time in men followed expectantly for stage T1c disease. J Urol. 2008 Mar;179(3):901-904; discussion 904-905.
Alousi, A.M.; Weisdorf, D.J.; Logan, B.R.; Bolanos-Meade, J.; Carter, S.; Difronzo, N.; Pasquini, M.; Goldstein, S.C.; Ho, V.T.; Hayes-Lattin, B.; Wingard, J.R.; Horowitz, M.M.; Levine, J.E. Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network. Blood. 2009 Jul 16;114(3):511-517.
Carlson, R.W.; Allred, D.C.; Anderson, B.O.; Burstein, H.J.; Carter, W.B.; Edge, S.B.; Erban, J.K.; Farrar, W.B.; Goldstein, L.J.; Gradishar, W.J.; Hayes, D.F.; Hudis, C.A.; Jahanzeb, M.; Kiel, K.; Ljung, B.M.; Marcom, P.K.; Mayer, I.A.; McCormick, B.; Nabell, L.M.; Pierce, L.J.; Reed, E.C.; Smith, M.L.; Somlo, G.; Theriault, R.L.; Topham, N.S.; Ward, J.H.; Winer, E.P.; Wolff, A.C. Breast cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2009 Feb;7(2):122-192.
Carter, H.; Chen, S.; Isik, L.; Tyekucheva, S.; Velculescu, V.E.; Kinzler, K.W.; Vogelstein, B.; Karchin, R. Cancer-specific high-throughput annotation of somatic mutations: computational prediction of driver missense mutations. Cancer Res. 2009 Aug 15;69(16):6660-6667.
Carter, R.E.; Huang, P. Cautionary note regarding the use of CIs obtained from Kaplan-Meier survival curves. J Clin Oncol. 2009 Jan 10;27(2):174-175.
Duffield, A.S.; Lee, T.K.; Miyamoto, H.; Carter, H.B.; Epstein, J.I. Radical prostatectomy findings in patients in whom active surveillance of prostate cancer fails. J Urol. 2009 Nov;182(5):2274-2278.
Greene, K.L.; Albertsen, P.C.; Babaian, R.J.; Carter, H.B.; Gann, P.H.; Han, M.; Kuban, D.A.; Sartor, A.O.; Stanford, J.L.; Zietman, A.; Carroll, P. Prostate specific antigen best practice statement: 2009 update. J Urol. 2009 Nov;182(5):2232-2241.
Kramer, B.S.; Hagerty, K.L.; Justman, S.; Somerfield, M.R.; Albertsen, P.C.; Blot, W.J.; Ballentine Carter, H.; Costantino, J.P.; Epstein, J.I.; Godley, P.A.; Harris, R.P.; Wilt, T.J.; Wittes, J.; Zon, R.; Schellhammer, P. Use of 5-alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline. J Clin Oncol. 2009 Mar 20;27(9):1502-1516.
Kramer, B.S.; Hagerty, K.L.; Justman, S.; Somerfield, M.R.; Albertsen, P.C.; Blot, W.J.; Carter, H.B.; Costantino, J.P.; Epstein, J.I.; Godley, P.A.; Harris, R.P.; Wilt, T.J.; Wittes, J.; Zon, R.; Schellhammer, P. Use of 5alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline. J Urol. 2009 Apr;181(4):1642-1657.
Loeb, S.; Carter, H.B. Words of wisdom. Re: Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population. Eur Urol. 2009 Feb;55(2):523-524.
Loeb, S.; Carter, H.B. Limitations and use of PSA derivatives in the screening and risk stratification of prostate cancer. Urol Oncol. 2009 Nov-Dec;27(6):583-584.
Loeb, S.; Carter, H.B.; Schaeffer, E.M.; Ferrucci, L.; Kettermann, A.; Metter, E.J. Should prostate specific antigen be adjusted for body mass index? Data from the Baltimore Longitudinal Study of Aging. J Urol. 2009 Dec;182(6):2646-2651.
Loeb, S.; Carter, H.B.; Walsh, P.C.; Isaacs, W.B.; Kettermann, A.; Tanaka, T.; Ferrucci, L.; Metter, E.J. Single nucleotide polymorphisms and the likelihood of prostate cancer at a given prostate specific antigen level. J Urol. 2009 Jul;182(1):101-104; discussion 105.
Loeb, S.; Kettermann, A.; Carter, H.B.; Ferrucci, L.; Metter, E.J.; Walsh, P.C. Prostate volume changes over time: results from the Baltimore Longitudinal Study of Aging. J Urol. 2009 Oct;182(4):1458-1462.
Loeb, S.; Schaeffer, E.M.; Chan, D.W.; Carter, H.B.; Walsh, P.C.; Sokoll, L.J. Investigation of human anti-mouse antibodies as potential cause of postprostatectomy PSA elevation. Urology. 2009 May;73(5):947-949.
Makarov, D.V.; Isharwal, S.; Sokoll, L.J.; Landis, P.; Marlow, C.; Epstein, J.I.; Partin, A.W.; Carter, H.B.; Veltri, R.W. Pro-prostate-specific antigen measurements in serum and tissue are associated with treatment necessity among men enrolled in expectant management for prostate cancer. Clin Cancer Res. 2009 Dec 1;15(23):7316-7321.
Randhawa, P.; Viscidi, R.; Carter, J.J.; Galloway, D.A.; Culp, T.D.; Huang, C.; Ramaswami, B.; Christensen, N.D. Identification of species-specific and cross-reactive epitopes in human polyomavirus capsids using monoclonal antibodies. J Gen Virol. 2009 Mar;90(Pt 3):634-639.
Schaeffer, E.M.; Carter, H.B.; Kettermann, A.; Loeb, S.; Ferrucci, L.; Landis, P.; Trock, B.J.; Metter, E.J. Prostate specific antigen testing among the elderly-when to stop? J Urol. 2009 Apr;181(4):1606-1614; discussion 1613-1604.
Tosoian, J.J.; Loeb, S.; Kettermann, A.; Landis, P.; Elliot, D.J.; Epstein, J.I.; Partin, A.W.; Carter, H.B.; Sokoll, L.J. Accuracy of PCA3 Measurement in Predicting Short-Term Biopsy Progression in an Active Surveillance Program. J Urol. 2009 Dec 12.
Bozic, I.; Antal, T.; Ohtsuki, H.; Carter, H.; Kim, D.; Chen, S.; Karchin, R.; Kinzler, K.W.; Vogelstein, B.; Nowak, M.A. Accumulation of driver and passenger mutations during tumor progression. Proc Natl Acad Sci U S A. 2010 Oct 26;107(43):18545-18550.
Parsons, D.W.; Li, M.; Zhang, X.; Jones, S.; Leary, R.J.; Lin, J.C.; Boca, S.M.; Carter, H.; Samayoa, J.; Bettegowda, C.; Gallia, G.L.; Jallo, G.I.; Binder, Z.A.; Nikolsky, Y.; Hartigan, J.; Smith, D.R.; Gerhard, D.S.; Fults, D.W.; Vandenberg, S.; Berger, M.S.; Marie, S.K.; Shinjo, S.M.; Clara, C.; Phillips, P.C.; Minturn, J.E.; Biegel, J.A.; Judkins, A.R.; Resnick, A.C.; Storm, P.B.; Curran, T.; He, Y.; Rasheed, B.A.; Friedman, H.S.; Keir, S.T.; McLendon, R.; Northcott, P.A.; Taylor, M.D.; Burger, P.C.; Riggins, G.J.; Karchin, R.; Parmigiani, G.; Bigner, D.D.; Yan, H.; Papadopoulos, N.; Vogelstein, B.; Kinzler, K.W.; Velculescu, V.E. The Genetic Landscape of the Childhood Cancer Medulloblastoma. Science. 2010 Dec 16.
Pierorazio, P.M.; Ferrucci, L.; Kettermann, A.; Longo, D.L.; Metter, E.J.; Carter, H.B. Serum testosterone is associated with aggressive prostate cancer in older men: results from the Baltimore Longitudinal Study of Aging. BJU Int. 2010 Sep 14;105(6):824-829.
Dr. Carter pioneered the concept of PSA rate of change (PSA velocity) as a marker of prostate cancer presence and the use of free PSA to predict the behavior of prostate cancer. He was the first to publish data demonstrating that an individuals personal prostate cancer screening program should be tailored to baseline PSA levels performed at an early age instead of using a one size fits all approach. Together with investigators at the Baltimore Longitudinal Study of Aging, Dr. Carter has investigated risk factors for development of prostate cancer and prostate enlargement including diet and life style.
Dr. Carter runs the Expectant Management Program for prostate cancer at Johns Hopkins. This program is designed to select men who are thought to have small volume cancers for whom no immediate treatment is a rational management option. In this program, Dr. Carter together with colleagues at the Brady Urological Institute, are seeking to define the biomarker changes, nuclear structural parameters, genetic profile, and diet/lifestyle factors that may help identify which men with prostate caner can safely forgo treatment for prostate cancer
Journal Citations
Carter, H.B.; Ferrucci, L.; Kettermann, A.; Landis, P.; Wright, E.J.; Epstein, J.I.; Trock, B.J.; Metter, E.J. Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst. 2006 Nov 1;98(21):1521-1527.
Makarov, D.V.; Carter, H.B. The discovery of prostate specific antigen as a biomarker for the early detection of adenocarcinoma of the prostate. J Urol. 2006 Dec;176(6 Pt 1):2383-2385.
Martin, P.J.; Weisdorf, D.; Przepiorka, D.; Hirschfeld, S.; Farrell, A.; Rizzo, J.D.; Foley, R.; Socie, G.; Carter, S.; Couriel, D.; Schultz, K.R.; Flowers, M.E.; Filipovich, A.H.; Saliba, R.; Vogelsang, G.B.; Pavletic, S.Z.; Lee, S.J. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. Design of Clinical Trials Working Group report. Biol Blood Marrow Transplant. 2006 May;12(5):491-505.
Parsons, J.K.; Carter, H.B.; Partin, A.W.; Windham, B.G.; Metter, E.J.; Ferrucci, L.; Landis, P.; Platz, E.A. Metabolic factors associated with benign prostatic hyperplasia. J Clin Endocrinol Metab. 2006 Jul;91(7):2562-2568.
Richman, J.M.; Carter, H.B.; Hanna, M.N.; Murphy, J.D.; Rowlingson, A.J.; Andrews, R.A.; Wu, C.L. Efficacy of periprostatic local anesthetic for prostate biopsy analgesia: a meta-analysis. Urology. 2006 Jun;67(6):1224-1228.
Warlick, C.; Trock, B.J.; Landis, P.; Epstein, J.I.; Carter, H.B. Delayed versus immediate surgical intervention and prostate cancer outcome. J Natl Cancer Inst. 2006 Mar 1;98(5):355-357.
Warlick, C.A.; Allaf, M.E.; Carter, H.B. Expectant treatment with curative intent in the prostate-specific antigen era: triggers for definitive therapy. Urol Oncol. 2006 Jan-Feb;24(1):51-57.
Berdeja, J.G.; Hess, A.; Lucas, D.M.; O'Donnell, P.; Ambinder, R.F.; Diehl, L.F.; Carter-Brookins, D.; Newton, S.; Flinn, I.W. Systemic interleukin-2 and adoptive transfer of lymphokine-activated killer cells improves antibody-dependent cellular cytotoxicity in patients with relapsed B-cell lymphoma treated with rituximab. Clin Cancer Res. 2007 Apr 15;13(8):2392-2399.
Carlson, R.W.; Anderson, B.O.; Burstein, H.J.; Carter, W.B.; Edge, S.B.; Farrar, W.B.; Goldstein, L.J.; Gradishar, W.J.; Hayes, D.F.; Hudis, C.A.; Jahanzeb, M.; Ljung, B.M.; Kiel, K.; Marks, L.B.; McCormick, B.; Nabell, L.M.; Pierce, L.J.; Reed, E.C.; Silver, S.M.; Smith, M.L.; Somlo, G.; Theriault, R.L.; Ward, J.H.; Winer, E.P.; Wolff, A.C. Invasive breast cancer. J Natl Compr Canc Netw. 2007 Mar;5(3):246-312.
Carter, H.B.; Kettermann, A.; Ferrucci, L.; Landis, P.; Metter, E.J. Prostate-specific antigen velocity risk count assessment: a new concept for detection of life-threatening prostate cancer during window of curability. Urology. 2007 Oct;70(4):685-690.
Carter, H.B.; Kettermann, A.; Warlick, C.; Metter, E.J.; Landis, P.; Walsh, P.C.; Epstein, J.I. Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience. J Urol. 2007 Dec;178(6):2359-2364; discussion 2364-2355.
Gonzalgo, M.L.; Carter, H.B. Update on PSA testing. J Natl Compr Canc Netw. 2007 Aug;5(7):737-742.
Kawachi, M.H.; Bahnson, R.R.; Barry, M.; Carroll, P.R.; Carter, H.B.; Catalona, W.J.; Epstein, J.I.; Etzioni, R.B.; Hemstreet, G.P., 3rd; Howe, R.J.; Kopin, J.D.; Lange, P.H.; Lilja, H.; Mohler, J.; Moul, J.; Nadler, R.B.; Patterson, S.; Pollack, A.; Presti, J.C.; Stroup, A.M.; Urban, D.A.; Wake, R.; Wei, J.T. Prostate cancer early detection. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2007 Aug;5(7):714-736.
Keller, E.T.; Rowley, D.R.; Tomlins, S.A.; Drake, C.G.; Kantoff, P.W.; Pienta, K.J.; Montie, J.E.; Carter, H.B.; Hruszkewicz, A.M.; Gomez, J.; Mohla, S.; Getzenberg, R.H. Eleventh Prouts Neck Meeting on Prostate Cancer: emerging strategies in prostate cancer therapy. Cancer Res. 2007 Oct 15;67(20):9613-9615.
Magheli, A.; Rais-Bahrami, S.; Carter, H.B.; Peck, H.J.; Epstein, J.I.; Gonzalgo, M.L. Subclassification of clinical stage T1 prostate cancer: impact on biochemical recurrence following radical prostatectomy. J Urol. 2007 Oct;178(4 Pt 1):1277-1280; discussion 1280-1271.
Berkowitz, J.; Carter, H.B.; Gearhart, J.P. Prostate cancer in patients with the bladder exstrophy-epispadias complex: insights and outcomes. Urology. 2008 Jun;71(6):1064-1066.
Jones, S.; Zhang, X.; Parsons, D.W.; Lin, J.C.; Leary, R.J.; Angenendt, P.; Mankoo, P.; Carter, H.; Kamiyama, H.; Jimeno, A.; Hong, S.M.; Fu, B.; Lin, M.T.; Calhoun, E.S.; Kamiyama, M.; Walter, K.; Nikolskaya, T.; Nikolsky, Y.; Hartigan, J.; Smith, D.R.; Hidalgo, M.; Leach, S.D.; Klein, A.P.; Jaffee, E.M.; Goggins, M.; Maitra, A.; Iacobuzio-Donahue, C.; Eshleman, J.R.; Kern, S.E.; Hruban, R.H.; Karchin, R.; Papadopoulos, N.; Parmigiani, G.; Vogelstein, B.; Velculescu, V.E.; Kinzler, K.W. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008 Sep 26;321(5897):1801-1806.
Loeb, S.; Kettermann, A.; Carter, H.B.; Ferrucci, L.; Metter, E.J.; Walsh, P.C. Does prostate growth confound prostate specific antigen velocity? Data from the Baltimore longitudinal study of aging. J Urol. 2008 Oct;180(4):1314-1317; discussion 1317.
Loeb, S.; Kettermann, A.; Ferrucci, L.; Landis, P.; Metter, E.J.; Carter, H.B. PSA doubling time versus PSA velocity to predict high-risk prostate cancer: data from the Baltimore Longitudinal Study of Aging. Eur Urol. 2008 Nov;54(5):1073-1080.
Makarov, D.V.; Marlow, C.; Epstein, J.I.; Miller, M.C.; Landis, P.; Partin, A.W.; Carter, H.B.; Veltri, R.W. Using nuclear morphometry to predict the need for treatment among men with low grade, low stage prostate cancer enrolled in a program of expectant management with curative intent. Prostate. 2008 Feb 1;68(2):183-189.
Osunkoya, A.O.; Carter, H.B.; Epstein, J.I. A clinicopathologic study of preoperative and postoperative findings with minute Gleason 3+3=6 cancer at radical prostatectomy. Urology. 2008 Sep;72(3):638-640.
Parsons, D.W.; Jones, S.; Zhang, X.; Lin, J.C.; Leary, R.J.; Angenendt, P.; Mankoo, P.; Carter, H.; Siu, I.M.; Gallia, G.L.; Olivi, A.; McLendon, R.; Rasheed, B.A.; Keir, S.; Nikolskaya, T.; Nikolsky, Y.; Busam, D.A.; Tekleab, H.; Diaz, L.A., Jr.; Hartigan, J.; Smith, D.R.; Strausberg, R.L.; Marie, S.K.; Shinjo, S.M.; Yan, H.; Riggins, G.J.; Bigner, D.D.; Karchin, R.; Papadopoulos, N.; Parmigiani, G.; Vogelstein, B.; Velculescu, V.E.; Kinzler, K.W. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008 Sep 26;321(5897):1807-1812.
Roddam, A.W.; Allen, N.E.; Appleby, P.; Key, T.J.; Ferrucci, L.; Carter, H.B.; Metter, E.J.; Chen, C.; Weiss, N.S.; Fitzpatrick, A.; Hsing, A.W.; Lacey, J.V., Jr.; Helzlsouer, K.; Rinaldi, S.; Riboli, E.; Kaaks, R.; Janssen, J.A.; Wildhagen, M.F.; Schroder, F.H.; Platz, E.A.; Pollak, M.; Giovannucci, E.; Schaefer, C.; Quesenberry, C.P., Jr.; Vogelman, J.H.; Severi, G.; English, D.R.; Giles, G.G.; Stattin, P.; Hallmans, G.; Johansson, M.; Chan, J.M.; Gann, P.; Oliver, S.E.; Holly, J.M.; Donovan, J.; Meyer, F.; Bairati, I.; Galan, P. Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies. Ann Intern Med. 2008 Oct 7;149(7):461-471, W483-468.
Schroder, F.H.; Carter, H.B.; Wolters, T.; van den Bergh, R.C.; Gosselaar, C.; Bangma, C.H.; Roobol, M.J. Early detection of prostate cancer in 2007. Part 1: PSA and PSA kinetics. Eur Urol. 2008 Mar;53(3):468-477.
Sheridan, T.B.; Carter, H.B.; Wang, W.; Landis, P.B.; Epstein, J.I. Change in prostate cancer grade over time in men followed expectantly for stage T1c disease. J Urol. 2008 Mar;179(3):901-904; discussion 904-905.
Alousi, A.M.; Weisdorf, D.J.; Logan, B.R.; Bolanos-Meade, J.; Carter, S.; Difronzo, N.; Pasquini, M.; Goldstein, S.C.; Ho, V.T.; Hayes-Lattin, B.; Wingard, J.R.; Horowitz, M.M.; Levine, J.E. Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network. Blood. 2009 Jul 16;114(3):511-517.
Carlson, R.W.; Allred, D.C.; Anderson, B.O.; Burstein, H.J.; Carter, W.B.; Edge, S.B.; Erban, J.K.; Farrar, W.B.; Goldstein, L.J.; Gradishar, W.J.; Hayes, D.F.; Hudis, C.A.; Jahanzeb, M.; Kiel, K.; Ljung, B.M.; Marcom, P.K.; Mayer, I.A.; McCormick, B.; Nabell, L.M.; Pierce, L.J.; Reed, E.C.; Smith, M.L.; Somlo, G.; Theriault, R.L.; Topham, N.S.; Ward, J.H.; Winer, E.P.; Wolff, A.C. Breast cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2009 Feb;7(2):122-192.
Carter, H.; Chen, S.; Isik, L.; Tyekucheva, S.; Velculescu, V.E.; Kinzler, K.W.; Vogelstein, B.; Karchin, R. Cancer-specific high-throughput annotation of somatic mutations: computational prediction of driver missense mutations. Cancer Res. 2009 Aug 15;69(16):6660-6667.
Carter, R.E.; Huang, P. Cautionary note regarding the use of CIs obtained from Kaplan-Meier survival curves. J Clin Oncol. 2009 Jan 10;27(2):174-175.
Duffield, A.S.; Lee, T.K.; Miyamoto, H.; Carter, H.B.; Epstein, J.I. Radical prostatectomy findings in patients in whom active surveillance of prostate cancer fails. J Urol. 2009 Nov;182(5):2274-2278.
Greene, K.L.; Albertsen, P.C.; Babaian, R.J.; Carter, H.B.; Gann, P.H.; Han, M.; Kuban, D.A.; Sartor, A.O.; Stanford, J.L.; Zietman, A.; Carroll, P. Prostate specific antigen best practice statement: 2009 update. J Urol. 2009 Nov;182(5):2232-2241.
Kramer, B.S.; Hagerty, K.L.; Justman, S.; Somerfield, M.R.; Albertsen, P.C.; Blot, W.J.; Ballentine Carter, H.; Costantino, J.P.; Epstein, J.I.; Godley, P.A.; Harris, R.P.; Wilt, T.J.; Wittes, J.; Zon, R.; Schellhammer, P. Use of 5-alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline. J Clin Oncol. 2009 Mar 20;27(9):1502-1516.
Kramer, B.S.; Hagerty, K.L.; Justman, S.; Somerfield, M.R.; Albertsen, P.C.; Blot, W.J.; Carter, H.B.; Costantino, J.P.; Epstein, J.I.; Godley, P.A.; Harris, R.P.; Wilt, T.J.; Wittes, J.; Zon, R.; Schellhammer, P. Use of 5alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline. J Urol. 2009 Apr;181(4):1642-1657.
Loeb, S.; Carter, H.B. Words of wisdom. Re: Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population. Eur Urol. 2009 Feb;55(2):523-524.
Loeb, S.; Carter, H.B. Limitations and use of PSA derivatives in the screening and risk stratification of prostate cancer. Urol Oncol. 2009 Nov-Dec;27(6):583-584.
Loeb, S.; Carter, H.B.; Schaeffer, E.M.; Ferrucci, L.; Kettermann, A.; Metter, E.J. Should prostate specific antigen be adjusted for body mass index? Data from the Baltimore Longitudinal Study of Aging. J Urol. 2009 Dec;182(6):2646-2651.
Loeb, S.; Carter, H.B.; Walsh, P.C.; Isaacs, W.B.; Kettermann, A.; Tanaka, T.; Ferrucci, L.; Metter, E.J. Single nucleotide polymorphisms and the likelihood of prostate cancer at a given prostate specific antigen level. J Urol. 2009 Jul;182(1):101-104; discussion 105.
Loeb, S.; Kettermann, A.; Carter, H.B.; Ferrucci, L.; Metter, E.J.; Walsh, P.C. Prostate volume changes over time: results from the Baltimore Longitudinal Study of Aging. J Urol. 2009 Oct;182(4):1458-1462.
Loeb, S.; Schaeffer, E.M.; Chan, D.W.; Carter, H.B.; Walsh, P.C.; Sokoll, L.J. Investigation of human anti-mouse antibodies as potential cause of postprostatectomy PSA elevation. Urology. 2009 May;73(5):947-949.
Makarov, D.V.; Isharwal, S.; Sokoll, L.J.; Landis, P.; Marlow, C.; Epstein, J.I.; Partin, A.W.; Carter, H.B.; Veltri, R.W. Pro-prostate-specific antigen measurements in serum and tissue are associated with treatment necessity among men enrolled in expectant management for prostate cancer. Clin Cancer Res. 2009 Dec 1;15(23):7316-7321.
Randhawa, P.; Viscidi, R.; Carter, J.J.; Galloway, D.A.; Culp, T.D.; Huang, C.; Ramaswami, B.; Christensen, N.D. Identification of species-specific and cross-reactive epitopes in human polyomavirus capsids using monoclonal antibodies. J Gen Virol. 2009 Mar;90(Pt 3):634-639.
Schaeffer, E.M.; Carter, H.B.; Kettermann, A.; Loeb, S.; Ferrucci, L.; Landis, P.; Trock, B.J.; Metter, E.J. Prostate specific antigen testing among the elderly-when to stop? J Urol. 2009 Apr;181(4):1606-1614; discussion 1613-1604.
Tosoian, J.J.; Loeb, S.; Kettermann, A.; Landis, P.; Elliot, D.J.; Epstein, J.I.; Partin, A.W.; Carter, H.B.; Sokoll, L.J. Accuracy of PCA3 Measurement in Predicting Short-Term Biopsy Progression in an Active Surveillance Program. J Urol. 2009 Dec 12.
Bozic, I.; Antal, T.; Ohtsuki, H.; Carter, H.; Kim, D.; Chen, S.; Karchin, R.; Kinzler, K.W.; Vogelstein, B.; Nowak, M.A. Accumulation of driver and passenger mutations during tumor progression. Proc Natl Acad Sci U S A. 2010 Oct 26;107(43):18545-18550.
Parsons, D.W.; Li, M.; Zhang, X.; Jones, S.; Leary, R.J.; Lin, J.C.; Boca, S.M.; Carter, H.; Samayoa, J.; Bettegowda, C.; Gallia, G.L.; Jallo, G.I.; Binder, Z.A.; Nikolsky, Y.; Hartigan, J.; Smith, D.R.; Gerhard, D.S.; Fults, D.W.; Vandenberg, S.; Berger, M.S.; Marie, S.K.; Shinjo, S.M.; Clara, C.; Phillips, P.C.; Minturn, J.E.; Biegel, J.A.; Judkins, A.R.; Resnick, A.C.; Storm, P.B.; Curran, T.; He, Y.; Rasheed, B.A.; Friedman, H.S.; Keir, S.T.; McLendon, R.; Northcott, P.A.; Taylor, M.D.; Burger, P.C.; Riggins, G.J.; Karchin, R.; Parmigiani, G.; Bigner, D.D.; Yan, H.; Papadopoulos, N.; Vogelstein, B.; Kinzler, K.W.; Velculescu, V.E. The Genetic Landscape of the Childhood Cancer Medulloblastoma. Science. 2010 Dec 16.
Pierorazio, P.M.; Ferrucci, L.; Kettermann, A.; Longo, D.L.; Metter, E.J.; Carter, H.B. Serum testosterone is associated with aggressive prostate cancer in older men: results from the Baltimore Longitudinal Study of Aging. BJU Int. 2010 Sep 14;105(6):824-829.
Research Interests
- Benign Prostatic Hyperplasia
- Prostate cancer
More Info
Languages
- English
Clinical Trials
- National Institute of Aging (BLSA)
Additional Resources
Facebook
Twitter
Sharecare
Blogs
YouTube
RSS
Podcasts